Affimed to Present at the 40th Annual J.P. Morgan Healthcare Conference
Affimed N.V. (Nasdaq: AFMD) announced that CEO Dr. Adi Hoess will present at the 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, at 10:30 a.m. EST. The event will showcase Affimed's commitment to immuno-oncology and its innovative ROCK® platform for cancer treatment. A live webcast of the presentation will be available on Affimed’s website and can be accessed for 30 days post-event. For further inquiries or to schedule meetings, contact Alex Fudukidis, the Director of Investor Relations.
- None.
- None.
HEIDELBERG, Germany, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that its Chief Executive Officer Dr. Adi Hoess will present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 10:30 a.m. Eastern Standard Time / 16:30 Central European Time.
A live webcast of the presentation may be accessed on Affimed’s website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/ or at https://jpmorgan.metameetings.net/events/healthcare22/sessions/40344-affimed/webcast?gpu_only=true&kiosk=true and will be available for 30 days following the event. For more information or to schedule a one-on-one meeting with Affimed management, please contact Alex Fudukidis via email at a.fudukidis@affimed.com or phone at +1 (917) 436-8102.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to give patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly owned and partnered single agent and combination therapy programs. The ROCK® platform predictably generates customized innate cell engager (ICE®) molecules, which use patients’ immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE®. Headquartered in Heidelberg, Germany, with offices in New York, NY, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients’ lives. For more about the company’s people, pipeline and partners, please visit: www.affimed.com.
Investor Relations Contact
Alexander Fudukidis
Director, Head of Investor Relations
E-Mail: a.fudukidis@affimed.com
Tel.: +1 (917) 436-8102
FAQ
What date is Affimed presenting at the J.P. Morgan Healthcare Conference?
Who is the CEO of Affimed that will present at the conference?
What is the stock symbol for Affimed?
Where can I watch Affimed's presentation live?
How long will the Affimed presentation be available for viewing after the event?
